Top

Published in:

01-08-2016 | Preclinical study

Expression of cancer-associated fibroblast-related proteins differs between invasive lobular carcinoma and invasive ductal carcinoma

Authors: Cheol Keun Park, Woo Hee Jung, Ja Seung Koo

Published in: Breast Cancer Research and Treatment | Issue 1/2016

Abstract

Cancer-associated fibroblasts (CAFs) are classified into various functional subtypes such as fibroblast activation protein-α (FAP-α), fibroblast specific protein-1 (FSP-1), platelet-derived growth factor receptor-α (PDGFR-α), and PDGFR-β. In this study, we compared the expression of CAF-related proteins in invasive lobular carcinoma (ILC) with those in invasive carcinoma of no special type (NST) and assessed the implications of the differences observed. Using tissue microarrays of 104 ILC and 524 invasive carcinoma (NST) cases, immunohistochemistry for CAF-related proteins [podoplanin, prolyl 4-hydroxylase, FAP-α, FSP-1/S100A4, PDGFR-α, PDGFR-β, and chondroitin sulfate proteoglycan (NG2)] was conducted. In invasive carcinoma (NST), tumor cells expressed a high level of PDGFR-α, whereas ILC tumor cells expressed high levels of podoplanin, prolyl 4-hydroxylase, FAP-α, and FSP-1/S100A4. In stromal cells of invasive carcinoma (NST), high expression levels of prolyl 4-hydroxylase, PDGFR-α, and NG2 were observed, whereas ILC stromal cells expressed high levels of FAP-α, FSP-1/S100A4, and PDGFR-β. In ILC, tumoral FSP-1/S100A4 positivity was associated with higher Ki-67 labeling index (p = 0.010) and non-luminal A type cancer (p = 0.014). Stromal PDGFR-α positivity was associated with lymph node metastasis (p = 0.011). On survival analysis of entire cases, tumoral FSP-1/S100A4 positivity (p = 0.002), stromal podoplanin positivity (p = 0.041), and stromal FSP-1/S100A4 negativity (p = 0.041) were associated with shorter disease-free survival; only tumoral FSP-1/S100A4 positivity (p = 0.044) was associated with shorter overall survival. In ILC, the expression of FAP-α and FSP-1/S100A4 was higher in both tumor and stromal cells than that observed in invasive carcinoma (NST). These results indicate that CAFs are a potential target in ILC treatment.

Available only for authorised users

Tavassoli FA, Devilee P, International Agency for Research on Cancer et al (2003) Pathology and genetics of tumours of the breast and female genital organs. IAPS Press, Lyon

Li CI, Anderson BO, Daling JR et al (2003) Trends in incidence rates of invasive lobular and ductal breast carcinoma. JAMA 289(11):1421–1424PubMedCrossRef

Li CI, Uribe DJ, Daling JR (2005) Clinical characteristics of different histologic types of breast cancer. Br J Cancer 93(9):1046–1052. doi:10.1038/sj.bjc.6602787 PubMedPubMedCentralCrossRef

Tot T (2000) The cytokeratin profile of medullary carcinoma of the breast. Histopathology 37(2):175–181. doi:10.1046/j.1365-2559.2000.00889.x PubMedCrossRef

Reeves GK, Beral V, Green J et al (2006) Hormonal therapy for menopause and breast-cancer risk by histological type: a cohort study and meta-analysis. Lancet Oncol 7(11):910–918. doi:10.1016/s1470-2045(06)70911-1 PubMedCrossRef

Lesser ML, Rosen PP, Kinne DW (1982) Multicentricity and bilaterality in invasive breast carcinoma. Surgery 91(2):234–240PubMed

Silverstein MJ, Lewinsky BS, Waisman JR et al (1994) Infiltrating lobular carcinoma. Is it different from infiltrating duct carcinoma? Cancer 73(6):1673–1677PubMedCrossRef

De Leeuw WJ, Berx G, Vos CB et al (1997) Simultaneous loss of E-cadherin and catenins in invasive lobular breast cancer and lobular carcinoma in situ. J Pathol 183(4):404–411. doi:10.1002/(sici)1096-9896(199712)183:4<404:aid-path1148>3.0.co;2-9 PubMedCrossRef

Tsutsui S, Ohno S, Murakami S et al (2003) Prognostic value of the combination of epidermal growth factor receptor and c-erbB-2 in breast cancer. Surgery 133(2):219–221. doi:10.1067/msy.2003.32 PubMedCrossRef

10.

Uehara H, Takahashi T, Oha M et al (2014) Exogenous fatty acid binding protein 4 promotes human prostate cancer cell progression. Int J Cancer. doi:10.1002/ijc.28903

11.

Franco OE, Shaw AK, Strand DW et al (2010) Cancer associated fibroblasts in cancer pathogenesis. Semin Cell Dev Biol 21(1):33–39. doi:10.1016/j.semcdb.2009.10.010 PubMedCrossRef

12.

Ostman A (2014) Cancer-associated fibroblasts: recent developments and emerging challenges. Semin Cancer Biol 25:1–2. doi:10.1016/j.semcancer.2014.02.004 PubMedCrossRef

13.

Desmouliere A, Guyot C, Gabbiani G (2004) The stroma reaction myofibroblast: a key player in the control of tumor cell behavior. Int J Dev Biol 48(5–6):509–517. doi:10.1387/ijdb.041802ad PubMedCrossRef

14.

De Wever O, Nguyen QD, Van Hoorde L et al (2004) Tenascin-C and SF/HGF produced by myofibroblasts in vitro provide convergent pro-invasive signals to human colon cancer cells through RhoA and Rac. FASEB J 18(9):1016–1018. doi:10.1096/fj.03-1110fje PubMed

15.

Sugimoto H, Mundel TM, Kieran MW et al (2006) Identification of fibroblast heterogeneity in the tumor microenvironment. Cancer Biol Ther 5(12):1640–1646PubMedCrossRef

16.

Pietras K, Sjoblom T, Rubin K et al (2003) PDGF receptors as cancer drug targets. Cancer Cell 3(5):439–443PubMedCrossRef

17.

Kraman M, Bambrough PJ, Arnold JN et al (2010) Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science 330(6005):827–830. doi:10.1126/science.1195300 PubMedCrossRef

18.

Kawase A, Ishii G, Nagai K et al (2008) Podoplanin expression by cancer associated fibroblasts predicts poor prognosis of lung adenocarcinoma. Int J Cancer 123(5):1053–1059. doi:10.1002/ijc.23611 PubMedCrossRef

19.

Kojima Y, Acar A, Eaton EN et al (2010) Autocrine TGF-beta and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts. Proc Natl Acad Sci USA 107(46):20009–20014. doi:10.1073/pnas.1013805107 PubMedPubMedCentralCrossRef

20.

Cortez E, Roswall P, Pietras K (2014) Functional subsets of mesenchymal cell types in the tumor microenvironment. Semin Cancer Biol 25:3–9. doi:10.1016/j.semcancer.2013.12.010 PubMedCrossRef

21.

Mao Y, Keller ET, Garfield DH et al (2013) Stromal cells in tumor microenvironment and breast cancer. Cancer Metastasis Rev 32(1–2):303–315. doi:10.1007/s10555-012-9415-3 PubMedPubMedCentralCrossRef

22.

Nakagawa S, Miki Y, Miyashita M et al (2016) Tumor microenvironment in invasive lobular carcinoma: possible therapeutic targets. Breast Cancer Res Treat 155(1):65–75. doi:10.1007/s10549-015-3668-9 PubMedCrossRef

23.

Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19(5):403–410PubMedCrossRef

24.

Hammond ME, Hayes DF, Dowsett M et al (2010) American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28(16):2784–2795. doi:10.1200/jco.2009.25.6529 PubMedPubMedCentralCrossRef

25.

Wolff AC, Hammond ME, Hicks DG et al (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 31(31):3997–4013. doi:10.1200/jco.2013.50.9984 PubMedCrossRef

26.

Henry LR, Lee HO, Lee JS et al (2007) Clinical implications of fibroblast activation protein in patients with colon cancer. Clin Cancer Res 13(6):1736–1741. doi:10.1158/1078-0432.ccr-06-1746 PubMedCrossRef

27.

Goldhirsch A, Wood WC, Coates AS et al (2011) Strategies for subtypes–dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22(8):1736–1747. doi:10.1093/annonc/mdr304 PubMedPubMedCentralCrossRef

28.

Jansson S, Bendahl PO, Grabau DA et al (2014) The three receptor tyrosine kinases c-KIT, VEGFR2 and PDGFRalpha, closely spaced at 4q12, show increased protein expression in triple-negative breast cancer. Plos One 9(7):e102176. doi:10.1371/journal.pone.0102176 PubMedPubMedCentralCrossRef

29.

Zhu Y, Wang Y, Guan B et al (2014) C-kit and PDGFRA gene mutations in triple negative breast cancer. Int J Clin Exp Pathol 7(7):4280–4285PubMedPubMedCentral

30.

Martin-Villar E, Megias D, Castel S et al (2006) Podoplanin binds ERM proteins to activate RhoA and promote epithelial-mesenchymal transition. J Cell Sci 119(Pt 21):4541–4553. doi:10.1242/jcs.03218 PubMedCrossRef

31.

Grau SJ, Trillsch F, Tonn JC et al (2015) Podoplanin increases migration and angiogenesis in malignant glioma. Int J Clin Exp Pathol 8(7):8663–8670PubMedPubMedCentral

32.

Xiong G, Deng L, Zhu J et al (2014) Prolyl-4-hydroxylase alpha subunit 2 promotes breast cancer progression and metastasis by regulating collagen deposition. BMC Cancer 14:1. doi:10.1186/1471-2407-14-1 PubMedPubMedCentralCrossRef

33.

Wasif N, Maggard MA, Ko CY et al (2010) Invasive lobular vs. ductal breast cancer: a stage-matched comparison of outcomes. Ann Surg Oncol 17(7):1862–1869. doi:10.1245/s10434-010-0953-z PubMedCrossRef

34.

Ito M, Hagiyama M, Mimae T et al (2014) alpha-Parvin, a pseudopodial constituent, promotes cell motility and is associated with lymph node metastasis of lobular breast carcinoma. Breast Cancer Res Treat 144(1):59–69. doi:10.1007/s10549-014-2859-0 PubMedCrossRef

35.

Catteau X, Simon P, Noel JC (2014) Myofibroblastic stromal reaction and lymph node status in invasive breast carcinoma: possible role of the TGF-beta1/TGF-betaR1 pathway. BMC Cancer 14:499. doi:10.1186/1471-2407-14-499 PubMedPubMedCentralCrossRef

36.

Song S, Ewald AJ, Stallcup W et al (2005) PDGFRbeta + perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival. Nat Cell Biol 7(9):870–879. doi:10.1038/ncb1288 PubMedPubMedCentralCrossRef

37.

Iacobuzio-Donahue CA, Argani P, Hempen PM et al (2002) The desmoplastic response to infiltrating breast carcinoma: gene expression at the site of primary invasion and implications for comparisons between tumor types. Cancer Res 62(18):5351–5357PubMed

38.

Shao ZM, Nguyen M, Barsky SH (2000) Human breast carcinoma desmoplasia is PDGF initiated. Oncogene 19(38):4337–4345. doi:10.1038/sj.onc.1203785 PubMedCrossRef

39.

Huang Y, Simms AE, Mazur A et al (2011) Fibroblast activation protein-alpha promotes tumor growth and invasion of breast cancer cells through non-enzymatic functions. Clin Exp Metastasis 28(6):567–579. doi:10.1007/s10585-011-9392-x PubMedCrossRef

40.

Jia J, Martin TA, Ye L et al (2014) FAP-alpha (Fibroblast activation protein-alpha) is involved in the control of human breast cancer cell line growth and motility via the FAK pathway. BMC Cell Biol 15:16. doi:10.1186/1471-2121-15-16 PubMedPubMedCentralCrossRef

41.

Jenkinson SR, Barraclough R, West CR et al (2004) S100A4 regulates cell motility and invasion in an in vitro model for breast cancer metastasis. Br J Cancer 90(1):253–262. doi:10.1038/sj.bjc.6601483 PubMedPubMedCentralCrossRef

42.

Wang L, Wang X, Liang Y et al (2012) S100A4 promotes invasion and angiogenesis in breast cancer MDA-MB-231 cells by upregulating matrix metalloproteinase-13. Acta Biochim Pol 59(4):593–598PubMed

43.

Michaut M, Chin SF, Majewski I et al (2016) Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer. Sci Rep 6:18517. doi:10.1038/srep18517 PubMedPubMedCentralCrossRef

44.

O’Connell JT, Sugimoto H, Cooke VG et al (2011) VEGF-A and Tenascin-C produced by S100A4+ stromal cells are important for metastatic colonization. Proc Natl Acad Sci USA 108(38):16002–16007. doi:10.1073/pnas.1109493108 PubMedPubMedCentralCrossRef

45.

Zhang J, Chen L, Liu X et al (2013) Fibroblast-specific protein 1/S100A4-positive cells prevent carcinoma through collagen production and encapsulation of carcinogens. Cancer Res 73(9):2770–2781. doi:10.1158/0008-5472.can-12-3022 PubMedCrossRef

46.

Cabezon T, Celis JE, Skibshoj I et al (2007) Expression of S100A4 by a variety of cell types present in the tumor microenvironment of human breast cancer. Int J Cancer 121(7):1433–1444. doi:10.1002/ijc.22850 PubMedCrossRef

47.

Zhang J, Chen L, Xiao M et al (2011) FSP1 + fibroblasts promote skin carcinogenesis by maintaining MCP-1-mediated macrophage infiltration and chronic inflammation. Am J Pathol 178(1):382–390. doi:10.1016/j.ajpath.2010.11.017 PubMedPubMedCentralCrossRef

48.

Eusebi V, Magalhaes F, Azzopardi JG (1992) Pleomorphic lobular carcinoma of the breast: an aggressive tumor showing apocrine differentiation. Hum Pathol 23(6):655–662PubMedCrossRef

49.

Bentz JS, Yassa N, Clayton F (1998) Pleomorphic lobular carcinoma of the breast: clinicopathologic features of 12 cases. Mod Pathol 11(9):814–822PubMed

50.

Narendra S, Jenkins SM, Khoor A et al (2015) Clinical outcome in pleomorphic lobular carcinoma: a case-control study with comparison to classic invasive lobular carcinoma. Ann Diagn Pathol 19(2):64–69. doi:10.1016/j.anndiagpath.2015.01.005 PubMedPubMedCentralCrossRef

51.

Simpson PT, Reis-Filho JS, Lambros MB et al (2008) Molecular profiling pleomorphic lobular carcinomas of the breast: evidence for a common molecular genetic pathway with classic lobular carcinomas. J Pathol 215(3):231–244. doi:10.1002/path.2358 PubMedCrossRef

52.

Ohlund D, Elyada E, Tuveson D (2014) Fibroblast heterogeneity in the cancer wound. J Exp Med 211(8):1503–1523. doi:10.1084/jem.20140692 PubMedPubMedCentralCrossRef

53.

Haubeiss S, Schmid JO, Murdter TE et al (2010) Dasatinib reverses cancer-associated fibroblasts (CAFs) from primary lung carcinomas to a phenotype comparable to that of normal fibroblasts. Mol Cancer 9:168. doi:10.1186/1476-4598-9-168 PubMedPubMedCentralCrossRef

54.

Brennen WN, Isaacs JT, Denmeade SR (2012) Rationale behind targeting fibroblast activation protein-expressing carcinoma-associated fibroblasts as a novel chemotherapeutic strategy. Mol Cancer Ther 11(2):257–266. doi:10.1158/1535-7163.mct-11-0340 PubMedPubMedCentralCrossRef

55.

Santos AM, Jung J, Aziz N et al (2009) Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice. J Clin Invest 119(12):3613–3625. doi:10.1172/jci38988 PubMedPubMedCentralCrossRef

56.

Scott AM, Wiseman G, Welt S et al (2003) A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin Cancer Res 9(5):1639–1647PubMed

57.

Neri S, Ishii G, Hashimoto H et al (2015) Podoplanin-expressing cancer-associated fibroblasts lead and enhance the local invasion of cancer cells in lung adenocarcinoma. Int J Cancer 137(4):784–796. doi:10.1002/ijc.29464 PubMedCrossRef

58.

Slany A, Haudek-Prinz V, Meshcheryakova A et al (2014) Extracellular matrix remodeling by bone marrow fibroblast-like cells correlates with disease progression in multiple myeloma. J Proteome Res 13(2):844–854. doi:10.1021/pr400881p PubMedCrossRef

59.

Garin-Chesa P, Old LJ, Rettig WJ (1990) Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc Natl Acad Sci USA 87(18):7235–7239PubMedPubMedCentralCrossRef

60.

Lee HO, Mullins SR, Franco-Barraza J et al (2011) FAP-overexpressing fibroblasts produce an extracellular matrix that enhances invasive velocity and directionality of pancreatic cancer cells. BMC Cancer 11:245. doi:10.1186/1471-2407-11-245 PubMedPubMedCentralCrossRef

61.

Liao D, Luo Y, Markowitz D et al (2009) Cancer associated fibroblasts promote tumor growth and metastasis by modulating the tumor immune microenvironment in a 4T1 murine breast cancer model. Plos One 4(11):e7965. doi:10.1371/journal.pone.0007965 PubMedPubMedCentralCrossRef

62.

Erez N, Truitt M, Olson P et al (2010) Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-kappaB-dependent manner. Cancer Cell 17(2):135–147. doi:10.1016/j.ccr.2009.12.041 PubMedCrossRef

63.

Pietras K, Pahler J, Bergers G et al (2008) Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting. Plos Med 5(1):e19. doi:10.1371/journal.pmed.0050019 PubMedPubMedCentralCrossRef

64.

Crawford Y, Kasman I, Yu L et al (2009) PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell 15(1):21–34. doi:10.1016/j.ccr.2008.12.004 CrossRefPubMed

65.

Ehnman M, Missiaglia E, Folestad E et al (2013) Distinct effects of ligand-induced PDGFRalpha and PDGFRbeta signaling in the human rhabdomyosarcoma tumor cell and stroma cell compartments. Cancer Res 73(7):2139–2149. doi:10.1158/0008-5472.can-12-1646 PubMedPubMedCentralCrossRef

66.

Pietras K, Ostman A, Sjoquist M et al (2001) Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res 61(7):2929–2934PubMed

67.

Pietras K, Rubin K, Sjoblom T et al (2002) Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res 62(19):5476–5484PubMed

68.

Cooke VG, LeBleu VS, Keskin D et al (2012) Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway. Cancer Cell 21(1):66–81. doi:10.1016/j.ccr.2011.11.024 PubMedPubMedCentralCrossRef

Title: Expression of cancer-associated fibroblast-related proteins differs between invasive lobular carcinoma and invasive ductal carcinoma
Authors: Cheol Keun Park
Woo Hee Jung
Ja Seung Koo
Publication date: 01-08-2016
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 1/2016
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-016-3929-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2016

Treatment of early-stage human epidermal growth factor 2-positive cancers among medicare enrollees: age and race strongly associated with non-use of trastuzumab

A pooled analysis of CYP2D6 genotype in breast cancer prevention trials of low-dose tamoxifen

Clinical and biological significance of RAD51 expression in breast cancer: a key DNA damage response protein

Author’s response to “letter to the editor: lower vitamin D status may explain racial disparities in all-cause mortality among younger commercially insured women with incident metastatic breast cancer”

Standardized measures of lobular involution and subsequent breast cancer risk among women with benign breast disease: a nested case–control study

Phase II studies of two different schedules of dasatinib in bone metastasis predominant metastatic breast cancer: SWOG S0622

Keynote webinar | Spotlight on antibody–drug conjugates in cancer